Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 3interventionalRules rewrite

Phase 3: testing Prasinezumab for Parkinson's Disease

This study wants to measure the how well it works, safety, and pharmacokinetics (PK) of prasinezumab compared with dummy treatment (placebo) in participants with early-stage Parkinson's disease (PD) on stable symptomatic this drug alone with levodopa.

Official registry: https://clinicaltrials.gov/study/NCT07174310 · Hoffmann-La Roche · enrollment listed as 900

What this phase means

Phase 3: this treatment already looked useful in smaller studies. Now it is tested in a large group, often against standard care or a dummy treatment, to see if it should be approved.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Prasinezumab, or Placebo. The registry lists allocation as randomized. This study wants to measure the how well it works, safety, and pharmacokinetics (PK) of prasinezumab compared with dummy treatment (placebo) in participants with early-stage Parkinson's disease (PD) on stable symptomatic this drug alone with levodopa.

They plan to enroll about 900 people at 192 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

Interventions: Prasinezumab, Placebo

Primary outcome (registry wording): Time to Confirmed Motor Progression Event on Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score

Who it is for (from inclusion criteria)

  • Ages 50 Years to 85 Years
  • Body weight within 40-110 kilograms (kg) (88-242 pounds \[lbs\]) and a body mass index within the range 18-34 kg/m2
  • Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria
  • Has received this drug alone treatment
  • An MDS-UPDRS Part IV score of 0 at screening and prior to randomization
  • Hoehn and Yahr (H\&Y) Stage 1 or 2 off medication at screening and prior to randomization
  • Agreement to adhere to the contraception requirements

Public study contact (from the registry)

Reference Study ID Number: BN44715 https://forpatients.roche.com/ No attachments to email below.

888-662-6728 (U.S. and Canada)

global-roche-genentech-trials@gene.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

192 listed

+ 139 sites outside the US on the same record

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Not a traditional drug phase: Medtronic Activa Tremor Control System for Parkinson's Disease

Background: \- Deep brain stimulation (DBS) is an approved surgery for certain movement disorders, like Parkinson's disease, that do not respond well to other treatments. DBS uses a battery-powered device called a neurostimulator (like a pacemaker) that is placed under the skin in the chest.

NCT01581580 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

RecruitingNot a traditional drug phaseClermont-Ferrand
Not a traditional drug phase: Development of a screening algorithm designed to determine a "dysmobility" profile in patients with chronic illness. for Joint Osteoarthritis

Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern.

NCT04375280 · Official ClinicalTrials.gov record · University Hospital, Clermont-Ferrand

FAQ about this NCT record

Is NCT07174310 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07174310?

Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07174310?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary